The publication is now available through FDLI: #FDA #NicotineRegulation #TobaccoLaw #EVapor To view or add a comment, sign in Were proud to share that Keller and Heckman LLPs Tobacco and EVapor team, led by Partner Azim Chowdhury, coauthored the Food and Drug Law Institute (FDLI)'s 2026 publication, Nicotine Delivery Products: Navigating FDAs Policies and Regulations in a Dynamic Environment, in collaboration with Latham & Watkins
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
We explain what is GLP in laboratory science, from quality regulations to the GLP-1 medications changing lives in 2026.

Real-World Examples: 250-Pound Person: Average loss: 56 pounds (22.5%) Final weight: 194 pounds Timeline: 18-20 months 200-Pound Person: Average loss: 45 pounds (22.5%) Final weight: 155 pounds Timeline: 18-20 months 300-Pound Person: Average loss: 67 pounds (22.5%) Final weight: 233 pounds Timeline: 20-24 months Dosing Schedule: Standard Escalation: Weeks 1-4: 2.5 mg weekly (starting dose) Weeks 5-8: 5 mg weekly Weeks 9-12: 7.5 mg weekly Weeks 13-16: 10 mg weekly (if tolerating well) Weeks 17-20: 12.5 mg weekly (if needed) Week 21+: 15 mg weekly (maximum dose for weight loss) Flexible Dosing: Not everyone needs maximum 15 mg dose Many achieve excellent results at 10 mg Provider adjusts based on results and tolerance Can stay at effective dose rather than pushing to maximum Side Effects: Most Common: Nausea: 30-37% (lower than semaglutide despite higher potency) Diarrhea: 19-23% Vomiting: 9-17% Constipation: 10-17% Abdominal discomfort: 8-11% Interesting Finding: Despite being more potent, tirzepatide causes less nausea and vomiting than semaglutide

Mounjaro for diabetes, Zepbound for obesity), that have put them in the spotlight
Zero adverse events across all groups No adverse events were reported in any of the three groups over the full 6-month treatment period